Insights & news

European Commission Announces Interim Measures to Avert Possibly Irreversible Consequences of Grail's Acquisition by Illumina

  • 29/10/2021
  • Articles

The European Commission (the Commission) announced today that it adopted interim measures to prevent Illumina from implementing its acquisition of Grail (see, attached press release). The move is in response to Illumina’s decision to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations between undertakings (the Merger Regulation)(see, Van Bael & Bellis Life Sciences News & Insights of 21 September 2021). According to the Commission, Illumina is in breach of Article 7 of the Merger Regulation which imposes a standstill obligation on concentrations notifiable under the Merger Regulation. These must not be implemented until after the Commission has approved them.
 
The Commission’s interim measures require Illumina to keep Grail separate and to have it run by an independent “Hold Separate Manager”. Additionally, Illumina and Grail are, subject to exceptions, prohibited from sharing confidential business information. Business interactions between the parties should occur at arm’s length, but Illumina should provide funding to Grail. Lastly and significantly, Grail is required to “work on alternative options to the transaction” to prepare for the possibility that the transaction has to be undone following the Commission’s merger review. Compliance with the interim measures will be monitored by a Monitoring Trustee. Commissioner Vestager claimed that the interim measures were designed to allow Grail and others to “continue developing their innovative cancer detection technology”.
 
The Commission pointed out that interim measures of this nature are a first and were necessary to tackle what it described as “an unprecedented early implementation of a concentration”. Not surprisingly, the Commission did not mention that its review of the transaction is in itself controversial and subject to legal review. This is because the transaction does not meet any of the thresholds for review under the Merger Regulation or national merger control laws (see, Van Bael & Bellis Life Sciences News & Insights of 22 April 2021, 7 May 2021, and 24 August 2021).
 
Today’s Commission decision does not interfere with existing procedural tracks, including the Commission’s substantive review of the transaction, the Commission’s inquiry into a possible breach by the parties of the standstill obligation and the parties’ challenge of the Commission’s review of the transaction before the General Court of the European Union.  

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 19/07/2022
    • Articles

    European Commission Continues to Pursue "Gun Jumping" Merger Control Proceedings against Illumina and Grail

    On 20 August 2021, the European Commission (the Commission) said that it would investigate whether Illumina’s decision, made public on 18 August 2021, to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations between undertakings (the Merger Regulation) is in breach of the “standstill obligation” provided for by Article 7, Merger Regulation. Pursuant to this provision, a concentration notifiable under the Merger Regulation must not be implemented until after the Commission has approved it (see, Van Bael & Bellis Life Sciences News and Insights of 24 August 2021).

    Read more
    • 15/07/2022
    • News

    European Commission Publishes Proposal for Regulation on Substances of Human Origin

    On 14 July 2022, the European Commission (the Commission) published its long-awaited Proposal for a Regulation on standards of quality and safety for substances of human origin intended for human application (COM(2022) 338 final; the proposed Regulation) and an accompanying Q&A document (see, attachments). The proposed Regulation updates the current regulatory framework to improve safety and quality standards applicable to substances of human origin (so-called SoHOs). SoHOs include blood, tissues, cells and any other substances of human origin like human breast milk and microbiota. SoHOs can be directly intended for human application but can also be used in preparations or in manufactured products. Article 2 of the proposed Regulation provides for a list of “SoHO activities” that fall within the scope of the proposed Regulation. The list includes activities such as donor recruitment, processing of SoHOs, distribution, import and export of SoHOs and human application of SoHOs.   The proposed Regulation will apply to all SoHOs. Only solid organs used for transplantation will remain regulated separately under the Organs Directive (Directive 2010/45/EU). In view of the broad definition of the term SoHOs, the proposed Regulation will be future-proof in the sense that it will automatically apply to new substances of human origin that can be applied to patients. A key aspect of the proposed Regulation is that it empowers the Commission to adopt implementing acts regarding patient, donor and offspring protection. However, in the absence of such implementing acts, “SoHO entities” (which are defined in Article 3(24) as “organisation[s] legally established in the Union that carr[y] out one or more of the SoHO activities”) will have to apply standards established by the European Centre for Disease Prevention and Control and the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. The aim is to ensure that technical rules applicable to SoHO activities remain updated and to avert the accumulation of obsolete rules which would stand in the way of novel SoHO-based treatments and new medical techniques. For purposes of enforcement, the Commission devised a supervision mechanism based on national Competent Authorities. Chapters II and III of the proposed Regulation are dedicated to, respectively, “Competent Authorities” and “SoHO Supervisory Activities”. The rules enable extensive coordination between the different national Competent Authorities and the Commission. According to the Commission, increased harmonisation in the field of SoHO activities between EU countries could bring significant improvements in treatments such as stem, cornea, or skin transplants. Facilitated exchanges of SoHOs could even save lives, especially for conditions like blood cancer for which blood supply is of critical importance. The proposed Regulation will now be discussed by the Council and the European Parliament. Once the final text is agreed, adopted and published, most of the provisions will take effect after a transition period of two years.

    Read more
    • 14/07/2022
    • Articles

    General Court Confirms European Commission's Power to Review Illumina-Grail Even Though EU and National Turnover Thresholds Are Not Reached

    Yesterday, the General Court of the European Union came down on the side of the European Commission (the Commission) in that agency’s dispute with genomics firm Illumina and held that the Commission has jurisdiction to examine Illumina's acquisition of cancer detection test start-up Grail, even though the transaction escapes the European and Member State turnover thresholds for review (case T-227/21, Illumina, Inc. v. European Commission – see, attachment).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *